Anika Therapeutics (ANIK) Net Income towards Common Stockholders (QoQ) (2010 - 2025)
Anika Therapeutics (ANIK) Net Income towards Common Stockholders (QoQ) (2010 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.23 Bn | 19.57 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.47 Bn | 15.08 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Anika Therapeutics | 286.33 Mn | 247.92 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -278.37% |
| Sep 30, 2025 | 24.96% |
| Jun 30, 2025 | 173.99% |
| Mar 31, 2025 | 95.28% |
| Dec 31, 2024 | 30.97% |
| Sep 30, 2024 | -1,244.44% |
| Jun 30, 2024 | 195.90% |
| Mar 31, 2024 | -115.81% |
| Dec 31, 2023 | 347.50% |
| Sep 30, 2023 | -138.56% |
| Jun 30, 2023 | 73.42% |
| Mar 31, 2023 | -202.42% |
| Dec 31, 2022 | 341.95% |
| Sep 30, 2022 | -46.39% |
| Jun 30, 2022 | 2.24% |
| Mar 31, 2022 | 10.08% |
| Dec 31, 2021 | -685.87% |
| Sep 30, 2021 | -91.55% |
| Jun 30, 2021 | 130.09% |
| Mar 31, 2021 | 118.08% |